« Previous Next » American Journal of Kidney Diseases
Volume 53, Issue 4, Supplement 4 , Pages S3-S10 , April 2009

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

Rohit Bhuriya, MD
- Department of Medicine, Chicago Medical School, North Chicago, IL
Suying Li, PhD
- Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
Shu-Cheng Chen, MS
- Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
Peter A. McCullough, MD, MPH
- Division of Cardiology, William Beaumont Hospital, Royal Oak, MI
- Division of Nutrition, William Beaumont Hospital, Royal Oak, MI
- Preventive Medicine, Department of Medicine, William Beaumont Hospital, Royal Oak, MI
George L. Bakris, MD
- Hypertensive Diseases Unit, Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, IL
- Address correspondence to George L. Bakris, MD, University of Chicago School of Medicine, 5841 S Maryland Ave, MC 1027, Chicago, IL 60637

Received 16 October 2008 ,Accepted 19 November 2008.

Cardiovascular disease prevalence stratified by parathyroid hormone (PTH) level. P < 0.001 for Cochran-Armitage trend test. PTH levels expressed in pg/mL and ng/L are equivalent.

Cardiovascular disease prevalence stratified by parathyroid hormone (PTH) level. P < 0.001 for Cochran-Armitage trend test. PTH levels expressed in pg/mL and ng/L are equivalent.
- Full-Size Image
- Download to PowerPoint